📰 Genitourinary Malignancies Program News
Genitourinary Malignancies Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genitourinary Malignancies Program. Real-time updates on events, politics, business and more.
July 19, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been evolution of the treatment mind-set that, at least for some cancers, “aggressive” might not necessarily be better. For many cancer patients, that might have been welcome news when […]
July 18, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been the e
July 11, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been evolution of the
July 7, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been evolu
July 7, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been evolu
June 27, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been evolu
June 26, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been the e
June 24, 2023
It is no secret that great strides continue to be made in cancer treatment, but probably the most notable publicized development of 2023 thus far has been the e
August 6, 2022
FinancialContent fully hosted finance channel
August 6, 2022
NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall...